These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes? Foreman BH; Chambliss ML J Fam Pract; 2004 Mar; 53(3):241-2. PubMed ID: 15000928 [No Abstract] [Full Text] [Related]
3. Losartan versus captopril in elderly patients with heart failure. Jensen BV; Nielsen SL Lancet; 1997 May; 349(9063):1473; author reply 1475. PubMed ID: 9164335 [No Abstract] [Full Text] [Related]
4. Losartan versus captopril in elderly patients with heart failure. Sechi LA; Catena C; Bartoli E Lancet; 1997 May; 349(9063):1474; author reply 1475. PubMed ID: 9164337 [No Abstract] [Full Text] [Related]
5. Losartan versus captopril in elderly patients with heart failure. Ball SG Lancet; 1997 May; 349(9063):1474; author reply 1475. PubMed ID: 9164338 [No Abstract] [Full Text] [Related]
6. Losartan versus captopril in elderly patients with heart failure. Fournier A; Achard JM; Fernandez LA Lancet; 1997 May; 349(9063):1473-4; author reply 1475. PubMed ID: 9164336 [No Abstract] [Full Text] [Related]
7. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications. Studney D Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787 [TBL] [Abstract][Full Text] [Related]
8. [Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes]. Suzuki H Nihon Rinsho; 2002 Oct; 60 Suppl 10():323-8. PubMed ID: 12430248 [No Abstract] [Full Text] [Related]
9. [What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension]. Eguchi K; Kario K; Shimada K Nihon Rinsho; 2002 Sep; 60 Suppl 9():679-84. PubMed ID: 12387069 [No Abstract] [Full Text] [Related]
10. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Villa E; Rábano A; Cazes M; Cloarec A; Ruilope LM; García-Robles R Am J Hypertens; 1997 Mar; 10(3):275-81. PubMed ID: 9056684 [TBL] [Abstract][Full Text] [Related]
11. Drug companies should not have the final say in the design of clinical trials. Kurtzman NA Am J Kidney Dis; 2001 Nov; 38(5):1113-4. PubMed ID: 11684568 [No Abstract] [Full Text] [Related]
12. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Cao Z; Bonnet F; Davis B; Allen TJ; Cooper ME Clin Sci (Lond); 2001 Jun; 100(6):591-9. PubMed ID: 11352773 [TBL] [Abstract][Full Text] [Related]
18. [ACE inhibitors or AT1 receptor antagonists?]. Riegger GA Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045 [No Abstract] [Full Text] [Related]
19. Losartan in patients with renal insufficiency. de Zeeuw D; Gansevoort RT; de Jong PE Can J Cardiol; 1995 Aug; 11 Suppl F():41F-44F. PubMed ID: 7664217 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. Ceriello A; Motz E N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779 [No Abstract] [Full Text] [Related] [Next] [New Search]